AEON Biopharma Appoints Rob Bancroft as CEO

Dow Jones

04-22

By Katherine Hamilton

AEON Biopharma named Rob Bancroft as its new chief executive.

The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings experience in the therapeutic toxin industry with 25 years of leadership under his belt.

Bancroft is set to step into the role on April 29. He previously worked as general manager of the therapeutics business at Revance Therapeutics.

Bancroft succeeds Marc Forth, who stepped down on April 4 to pursue another opportunity.

Forth received total compensation of about $4 million as chief executive in 2023, according to a separate filing with the Securities and Exchange Commission.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 21, 2025 16:25 ET (20:25 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2529588453"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2529588453\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2529588453?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-22 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529588453","market":"sh","top_or_hot":-1,"title":"AEON Biopharma Appoints Rob Bancroft as CEO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/AEON\">AEON Biopharma</a> named Rob Bancroft as its new chief executive. \n</p>\n<p>\n  The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings experience in the therapeutic toxin industry with 25 years of leadership under his belt. \n</p>\n<p>\n  Bancroft is set to step into the role on April 29. He previously worked as general manager of the therapeutics business at Revance <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  Bancroft succeeds Marc Forth, who stepped down on April 4 to pursue another opportunity. \n</p>\n<p>\n  Forth received total compensation of about $4 million as chief executive in 2023, according to a separate filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2025 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AEON Biopharma Appoints Rob Bancroft as CEO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAEON Biopharma Appoints Rob Bancroft as CEO\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-04-22 04:25</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/AEON\">AEON Biopharma</a> named Rob Bancroft as its new chief executive. \n</p>\n<p>\n  The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings experience in the therapeutic toxin industry with 25 years of leadership under his belt. \n</p>\n<p>\n  Bancroft is set to step into the role on April 29. He previously worked as general manager of the therapeutics business at Revance <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  Bancroft succeeds Marc Forth, who stepped down on April 4 to pursue another opportunity. \n</p>\n<p>\n  Forth received total compensation of about $4 million as chief executive in 2023, according to a separate filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 21, 2025 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AEON","symbol_name":"AEON Biopharma","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2529588453","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529588453","pubTimestamp":1745267100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AEON Biopharma named Rob Bancroft as its new chief executive.The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings experience in the therapeutic toxin industry with 25 years of leadership under his belt.Bancroft is set to step into the role on April 29. He previously worked as general manager of the therapeutics business at Revance Therapeutics.Bancroft succeeds Marc Forth, who stepped down on April 4 to pursue another opportunity.Forth received total compensation of about $4 million as chief executive in 2023, according to a separate filing with the Securities and Exchange Commission.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AEON":"AEON Biopharma"},"translate_title":"AEON Biopharma任命Rob Bancroft为首席执行官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AEON":1},"content_text":"By Katherine Hamilton \n\n\nAEON Biopharma named Rob Bancroft as its new chief executive. \n\n\n  The Irvine, Calif. biopharmaceutical company, which is working on developing an alternative to Botox, said Monday Bancroft brings experience in the therapeutic toxin industry with 25 years of leadership under his belt. \n\n\n  Bancroft is set to step into the role on April 29. He previously worked as general manager of the therapeutics business at Revance Therapeutics. \n\n\n  Bancroft succeeds Marc Forth, who stepped down on April 4 to pursue another opportunity. \n\n\n  Forth received total compensation of about $4 million as chief executive in 2023, according to a separate filing with the Securities and Exchange Commission. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2025 16:25 ET (20:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}